| Date | Upside/Downside | Analyst Firm | Price Target Change | Rating Change | Previous / Current Rating |
|---|---|---|---|---|---|
| 06/29/2022 | — | William Blair | Downgrades | Outperform → Market Perform | |
| 06/05/2020 | 620.46% | HC Wainwright & Co. | $3 → $2 | Maintains | Buy |
| 03/31/2020 | 980.69% | HC Wainwright & Co. | $6 → $3 | Maintains | Buy |
| 04/09/2019 | 1701.15% | Canaccord Genuity | $19 → $5 | Maintains | Buy |
| 03/11/2019 | 2421.61% | HC Wainwright & Co. | → $7 | Initiates Coverage On | → Buy |
| 07/24/2017 | 7104.61% | Jefferies | → $20 | Initiates Coverage On | → Buy |
| 07/24/2017 | 6744.38% | B of A Securities | → $19 | Initiates Coverage On | → Buy |
| 07/24/2017 | 6744.38% | Canaccord Genuity | → $19 | Initiates Coverage On | → Buy |
Aileron Therapeutics Questions & Answers
The latest price target for Aileron Therapeutics (NASDAQ: ALRN) was reported by William Blair on June 29, 2022. The analyst firm set a price target for $0.00 expecting ALRN to fall to within 12 months (a possible -100.00% downside). 1 analyst firms have reported ratings in the last year.
The latest analyst rating for Aileron Therapeutics (NASDAQ: ALRN) was provided by William Blair, and Aileron Therapeutics downgraded their market perform rating.
Analysts arrive at stock ratings after doing extensive research, which includes going through public financial statements, talking to executives and customers of Aileron Therapeutics, and listening in to earnings conference calls. Most analysts do this every three months, so you should get 4 ratings per company per firm each year. The last rating for Aileron Therapeutics was filed on June 29, 2022 so you should expect the next rating to be made available sometime around June 29, 2023.
While ratings are subjective and will change, the latest Aileron Therapeutics (ALRN) rating was a downgraded with a price target of $0.00 to $0.00. The current price Aileron Therapeutics (ALRN) is trading at is $0.28, which is out of the analyst's predicted range.
